Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I SAD of N-MCT in Healthy Volunteers
NCT02778386Phase 1Unknown
- Sponsor
- N&N Pharmaceuticals
- Start
- Apr 2016
- Primary completion
- Dec 2016
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of n-methanocarbathymidine in herpes simplex virus infection and varicella zoster virus infection (4 cohorts), sponsored by N&N Pharmaceuticals. Primary endpoint: Safety and Tolerability of N-MCT at Day 7. Status: unknown.
02
Drugs
n-methanocarbathymidine
03
Conditions
herpes simplex virus infectionvaricella zoster virus infection
Beyond the preview
Go deeper on NCT02778386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02778386.